ArticleOncotarget2015
The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Data-Driven Visualization of the Dynamics of Antimicrobial Peptides in Cell Death.Probiotics and antimicrobial proteins · 2025Review
- Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth.Cell death discovery · 2024Article
- LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells.Frontiers in immunology · 2024Article
- Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth.Research square · 2023Article
- ΔM4: Membrane-Active Peptide with Antitumoral Potential against Human Skin Cancer Cells.Membranes · 2023Article
- Immunogenic Cell Death in Hematological Malignancy Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Antimicrobial Peptides Mediate Apoptosis by Changing Mitochondrial Membrane Permeability.International journal of molecular sciences · 2022Review
- Biophysical Characterization of LTX-315 Anticancer Peptide Interactions with Model Membrane Platforms: Effect of Membrane Surface Charge.International journal of molecular sciences · 2022Article
- Peptide Aggregation Induced Immunogenic Rupture (PAIIR).Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Intratumoural administration and tumour tissue targeting of cancer immunotherapies.Nature reviews. Clinical oncology · 2021Review
- Peptides that immunoactivate the tumor microenvironment.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Synthetic Peptide ΔM4-Induced Cell Death Associated with Cytoplasmic Membrane Disruption, Mitochondrial Dysfunction and Cell Cycle Arrest in Human Melanoma Cells.Molecules (Basel, Switzerland) · 2020Article
- Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier & targeting ligand.Biomaterials · 2020Review
- Antimicrobial Peptide TP4 Targets Mitochondrial Adenine Nucleotide Translocator 2.Marine drugs · 2020Article
- Cell cycle progression data on human skin cancer cells with anticancer synthetic peptide LTX-315 treatment.Data in brief · 2020Article
- LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects.Cell stress · 2019Article
- Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.Breast cancer research : BCR · 2019Article
- Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals.Cell death & disease · 2018Article
- The anticancer peptide RT53 induces immunogenic cell death.PloS one · 2018Article
- Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications.Oncotarget · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
LTX-315 has been developed as an amphipathic cationic peptide that kills cancer cells. Here, we investigated the putative involvement of mitochondria in the cytotoxic action of LTX-315. Subcellular fractionation of LTX-315-treated cells, followed by mass spectrometric quantification, revealed that the agent was enriched in mitochondria. LTX-315 caused an immediate arrest of mitochondrial respiration without any major uncoupling effect. Accordingly, LTX-315 disrupted the mitochondrial network, dissipated the mitochondrial inner transmembrane potential, and caused the release of mitochondrial intermembrane proteins into the cytosol. LTX-315 was relatively inefficient in stimulating mitophagy. Cells lacking the two pro-apoptotic multidomain proteins from the BCL-2 family, BAX and BAK, were less susceptible to LTX-315-mediated killing. Moreover, cells engineered to lose their mitochondria (by transfection with Parkin combined with treatment with a protonophore causing mitophagy) were relatively resistant against LTX-315, underscoring the importance of this organelle for LTX-315-mediated cytotoxicity. Altogether, these results support the notion that LTX-315 kills cancer cells by virtue of its capacity to permeabilize mitochondrial membranes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.